Community Trust & Investment Co. Sells 8,599 Shares of IQVIA Holdings Inc. $IQV

Community Trust & Investment Co. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 100,312 shares of the medical research company’s stock after selling 8,599 shares during the period. IQVIA accounts for about 1.2% of Community Trust & Investment Co.’s investment portfolio, making the stock its 23rd largest holding. Community Trust & Investment Co.’s holdings in IQVIA were worth $22,611,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Eubel Brady & Suttman Asset Management Inc. purchased a new stake in shares of IQVIA during the 3rd quarter valued at $14,278,000. Eagle Rock Investment Company LLC grew its position in IQVIA by 33.6% in the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after acquiring an additional 11,657 shares in the last quarter. OPTIMAS CAPITAL Ltd bought a new position in IQVIA in the third quarter valued at $4,008,000. Amundi raised its position in IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after purchasing an additional 405,250 shares in the last quarter. Finally, EDENTREE ASSET MANAGEMENT Ltd bought a new stake in IQVIA during the third quarter worth about $7,368,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.6%

NYSE IQV opened at $167.14 on Tuesday. The firm has a market cap of $28.36 billion, a PE ratio of 21.27, a price-to-earnings-growth ratio of 1.60 and a beta of 1.40. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The stock has a 50-day moving average of $192.66 and a 200-day moving average of $206.07. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

IQV has been the topic of several recent research reports. Mizuho set a $215.00 price objective on IQVIA in a research report on Monday, February 23rd. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a report on Friday, March 6th. Morgan Stanley set a $240.00 target price on IQVIA in a research note on Wednesday, February 11th. Royal Bank Of Canada started coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. Finally, Evercore reissued an “outperform” rating and set a $225.00 price target on shares of IQVIA in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.